Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3

BACKGROUND: Most current guidelines do not recommend the serial analysis of tumour marker CA 15.3 in the follow-up of asymptomatic patients treated for early breast cancer (EBC). These guidelines are based on small-scale studies carried out in an era with more limited treatment options than today. I...

Descripción completa

Detalles Bibliográficos
Autores principales: De Cock, L., Heylen, J., Wildiers, A., Punie, K., Smeets, A., Weltens, C., Neven, P., Billen, J., Laenen, A., Wildiers, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282974/
https://www.ncbi.nlm.nih.gov/pubmed/34271308
http://dx.doi.org/10.1016/j.esmoop.2021.100203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282974/
https://www.ncbi.nlm.nih.gov/pubmed/34271308
http://dx.doi.org/10.1016/j.esmoop.2021.100203

Ejemplares similares